Nuvalent (NUVL)

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

的Nuvalent, Inc. Class A Common Stock（NUVL）股票的价格今天是，自市场开启。该公司市值为$77.78亿，日交易量为股。前一交易日收盘价为 。

您准备好开始了吗？按照以下步骤操作，或阅读我们关于在Kraken上从10美元起购买Nuvalent股票的指南。